NOVEL REVERSE ADJUVANT FOR VACCINE ENHANCEMENT

用于增强疫苗效果的新型反向佐剂

• 批准号: 7573075
• 负责人: Ian NICHOLAS Crispe
• 金额: $ 22.91万
• 依托单位: SEATTLE BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-14 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7573075
• 关键词: Acquired Immunodeficiency Syndrome; Adjuvant; Bacteria; Biology; CD8B1 gene; Cell Adhesion Molecules; Clinical; Data; Disease; Drug toxicity; Effectiveness; Endotoxins; Experimental Models; Future; Genetic; HIV; Health; Hepatic; Hepatitis; Hepatitis C virus; Human; Immune; Immune response; Immunity; Immunologic Memory; Infection; Influenza; Influenza A Virus, H5N1 Subtype; Intercellular adhesion molecule 1; Intestines; Kupffer Cells; Liver; Malaria; Memory; Minority; Molecular; Mononuclear; Mus; Parasites; Pathway interactions; Patients; Pattern recognition receptor; Peptide/MHC Complex; Phagocytes; Pharmaceutical Preparations; Population; Radiation Chimera; Research; Resistance; Sepsis; Signal Pathway; Signal Transduction; T memory cell; T-Lymphocyte; TLR4 gene; Testing; Vaccination; Vaccine Adjuvant; Vaccine Clinical Trial; Vaccines; Vascular Cell Adhesion Molecule-1; base; hepatic sinusoid; influenza virus strain; influenzavirus; inhibitor/antagonist; liver function; mouse model; novel; novel strategies; public health relevance; research study; response; vaccine development; vaccine efficacy

DESCRIPTION (provided by applicant): Our research has revealed an unexpected aspect of the biology of the pattern recognition receptor, TLR-4. This molecule is expressed in the liver, principally on Kupffer cells. The engagement of liver TLR-4 by endotoxin derived from the intestinal bacteria promotes the expression of adhesion molecules in the hepatic sinusoids. Our Preliminary Data show that the TLR-4-dependent trapping of CD8+ T cells in the liver limits the size of systemic immune responses, and also of memory responses. In this proposal, we will test whether this mechanism can be exploited to enhance the effectiveness of a vaccine. Thus, we will prime influenza-specific CD8+ T cells either in mice congenitally lacking TLR-4, or in mice treated with Eritoran, a TLR-4 inhibitor that is already sanctioned for use in humans with severe sepsis. If this project is successful, we will have obtained proof-of-concept data that justify a new concept in vaccine biology. We term this the "reverse adjuvant" strategy, since it promotes CD8+ T cell responses via the inhibition of a molecule that more commonly acts to enhance immune responses. PUBLIC HEALTH RELEVANCE: Many important diseases, including malaria, hepatitis and AIDS, could be eliminated by successful vaccines. However, such vaccines are elusive. This project aims to develop a new approach to making vaccines more effective.

描述（由申请人提供）：我们的研究揭示了模式识别受体TLR-4生物学的一个意想不到的方面。该分子在肝脏中表达，主要在枯否细胞上。来自肠细菌的内毒素与肝TLR-4的结合促进了肝血窦中粘附分子的表达。我们的初步数据表明，TLR-4依赖性捕获的CD 8 + T细胞在肝脏中限制了全身免疫反应的大小，也限制了记忆反应。在这项建议中，我们将测试是否可以利用这种机制来提高疫苗的有效性。因此，我们将在先天性缺乏TLR-4的小鼠中，或在用TLR-4抑制剂治疗的小鼠中，引发流感特异性CD 8 + T细胞，TLR-4抑制剂已经被批准用于严重脓毒症的人类。如果这个项目成功，我们将获得证明疫苗生物学新概念的概念验证数据。我们称之为“反向佐剂”策略，因为它通过抑制更常用于增强免疫应答的分子来促进CD 8 + T细胞应答。公共卫生相关性：许多重要的疾病，包括疟疾、肝炎和艾滋病，可以通过成功的疫苗来消除。然而，这种疫苗是难以捉摸的。该项目旨在开发一种使疫苗更有效的新方法。